Lunai Bioworks (NASDAQ:LNAI – Get Free Report) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a note issued to investors on Friday.
Lunai Bioworks Stock Up 4.9%
NASDAQ:LNAI opened at $1.29 on Friday. Lunai Bioworks has a 1 year low of $1.13 and a 1 year high of $21.00. The firm has a market capitalization of $22.20 million, a PE ratio of -0.17 and a beta of 0.39.
Lunai Bioworks (NASDAQ:LNAI – Get Free Report) last released its quarterly earnings results on Monday, September 29th. The company reported ($7.60) earnings per share (EPS) for the quarter.
About Lunai Bioworks
Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.
Featured Articles
- Five stocks we like better than Lunai Bioworks
- 3 Best Fintech Stocks for a Portfolio Boost
- Why the Precious Metal Nobody Talks About Could Be Your Best Bet
- Insider Trading – What You Need to Know
- Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Receive News & Ratings for Lunai Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lunai Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
